Daiichi Sankyo Company, Limited

Asubio Pharma Co. Ltd.

Ausbio Pharma Co., Ltd.

Hidenobu Murafuji

Hidekazu Inoue

Yasuhiro Hayashi

Yasuyuki Takeda

Yamato Suzuki

Toshiharu Noji

Satoshi Muneoka

Bitoku Takahashi

Rie Inaba

Cystic fibrosis is developed through mutation of Cystic Fibrosis Transmembrane conductance Regulator (CFTR), which is one type of chloride channel. An object of the present invention is to provide compounds effective in the treatment of cystic fibrosis that open a chloride channel different from CFTR, which is the cause of the disease, and do not depend on CFTR. Compounds of the present invention are compounds or pharmaceutically acceptable salts thereof that open calcium dependent chloride channels (CaCCs) via G-protein coupled receptor 39 (GPR39) agonism to have strong chloride ion-secretory action, and are represented by the following general formula (I): General formula (I): wherein,

Pyrimidine derivative

To provide thienopyrazole derivatives inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic diseases, inflammatory diseases or immunologic diseases. The compound is thienopyrazole compound represented by the following formula (I): [wherein, especially, Ris a cyclohexyl, a cycloheptyl group or a tetrahydropyranyl group; Ris methyl; Ris a hydrogen atom; and Ris a group: &#x2014;CONRR(in which any one of Rand Ris a hydrogen atom)].

Thienopyrazole derivative having PDE7 inhibitory activity

To provide the compounds inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic disease, inflammatory disease or immunologic disease. The compound is pyridinylpyrazolo-pyrimidinone compound represented by the following formula (IA) or (IB): especially, Ris cyclohexyl or cycloheptyl group, Ris methyl; Ris a group: &#x2014;NRRor &#x2014;S(O)R;hydrogen atom; nitro group; cyano group; a halogen atom; heteroaryl group; and Ris methoxy or ethoxy group.

Pyridinylpyrazolopyrimidinone derivatives as PDE 7 inhibitors

The present invention provides the compounds inhibiting PDE 7 selectively, and therefore, enhances cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic disease, inflammatory disease or immunologic disease. The compound is imidazotriazinone compound represented by the following formula (IA) or (IB): especially, R1 is cyclohexyl group, R2 is methyl group; R3 is a hydrogen atom; nitro group; cyano group; a halogen atom; heteroaryl group; substituted or unsubstituted C1-C6 alkyl group; substituted or unsubstituted C2-C6 alkenyl group; saturated or unsaturated heterocycloalkyl group which is substituted or unsubstituted; a group: &#x2014;NR5R6, &#x2014;C(O)R7, &#x2014;SO2R7, &#x2014;OR8, &#x2014;NR8COR7, &#x2014;NR8S02R7; A is CR4; and B is CH. 

Imidazotriazinone derivatives as PDE 7 (phosphodiesterase 7) inhibitors

Pyrazolopyrimidinone derivatives expressed by the following general formula (IA) or (IB): where the symbols are as disclosed in the specification, are provided as desired compounds. These compounds selectively inhibiting PDE7, thereby increasing the intracellular cAMP level and inhibiting the activation of T cells. Thus, these compounds are useful for prevention and treatment of various allergic diseases and inflammatory or immunological diseases.

Growing community of inventors

Osaka, Japan

Hidenobu Murafuji